APA (7th ed.) Citation

KA, P., A, B., L, P., M, O., S, B., M, G., . . . MG, L. (2023). Long-term safety and efficacy of risankizumab for the treatment of moderate-to-severe plaque psoriasis: Interim analysis of the LIMMitless open-label extension trial up to 5 years of follow-up. Journal of the American Academy of Dermatology, 89(6), 1149. https://doi.org/10.1016/j.jaad.2023.07.1024

Chicago Style (17th ed.) Citation

KA, Papp, et al. "Long-term Safety and Efficacy of Risankizumab for the Treatment of Moderate-to-severe Plaque Psoriasis: Interim Analysis of the LIMMitless Open-label Extension Trial Up to 5 years of Follow-up." Journal of the American Academy of Dermatology 89, no. 6 (2023): 1149. https://doi.org/10.1016/j.jaad.2023.07.1024.

MLA (9th ed.) Citation

KA, Papp, et al. "Long-term Safety and Efficacy of Risankizumab for the Treatment of Moderate-to-severe Plaque Psoriasis: Interim Analysis of the LIMMitless Open-label Extension Trial Up to 5 years of Follow-up." Journal of the American Academy of Dermatology, vol. 89, no. 6, 2023, p. 1149, https://doi.org/10.1016/j.jaad.2023.07.1024.